Ernexa Therapeutics Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
ERNA$2.05+9.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except par value amounts)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash | $5,575 | $1,884 |
| Other receivables | 58 | 95 |
| Due from related party | - | 750 |
| Prepaid expenses and other current assets | 1,095 | 404 |
| Total current assets | 6,728 | 3,133 |
| Property and equipment, net | 73 | 94 |
| Right-of-use assets - operating leases, net | 278 | 453 |
| Goodwill | - | 2,044 |
| Other assets | 25 | 110 |
| Total assets | $7,104 | $5,834 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,356 | $1,125 |
| Accrued expenses | 773 | 898 |
| Income taxes payable | - | 3 |
| Operating lease liabilities, current | 171 | 213 |
| Due to related party | 250 | 750 |
| Contingent consideration liability | - | 41 |
| Other current liabilities | 64 | 83 |
| Total current liabilities | 2,614 | 3,113 |
| Operating lease liabilities, non-current | 138 | 277 |
| Other liabilities | 1 | 43 |
| Total liabilities | 2,753 | 3,433 |
| Stockholders’ equity: | ||
| Preferred stock, $0.005 par value, 1,000 shares authorized, 156 designated and outstanding of Series A convertible preferred stock at September 30, 2026 and December 31, 2025, $156 liquidation preference | 1 | 1 |
| Common stock, $0.005 par value, 150,000 shares authorized at September 30, 2026 and December 31, 2025, 1,645 and 314 issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 8 | 2 |
| Additional paid-in capital | 262,442 | 248,034 |
| Accumulated deficit | (258,100) | (245,636) |
| Total stockholders’ equity | 4,351 | 2,401 |
| Total liabilities and stockholders’ equity | $7,104 | $5,834 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.